Phase I Clinical Trial of Gm-Csf - Gregory Sarna

Abstract

Funding Agency

Agency: National Institute of Health (NIH)
Institute: Division of Cancer Treatment (NCI)
Type: Research and Development Contracts (N01)
Project #: N01CM047682-002
Application #: 3612221
Study Section

Project Start: 1988-06-30
Project End
Budget Start: 1988-06-30
Budget End: 1989-08-29
Support Year
Fiscal Year: 1988
Total Cost
Indirect Cost

Institution

Name: University of California Los Angeles
Department
Type: Schools of Medicine
DUNS #: 119132785

City: Los Angeles
State: CA
Country: United States
Zip Code: 90095

Related projects


NIH 1991 N01 CM	Phase Ib Trial of Immunotherapy/IL-2-Cytotoxic Cells Sarna, Gregory P. / University of California Los Angeles
NIH 1990 N01 CM	Phase Ib Trial of Immunotherapy/IL-2-Cytotoxic Cells Sarna, Gregory P. / University of California Los Angeles
NIH 1989 N01 CM	Phase Ib Trial of Immunotherapy/IL-2-Cytotoxic Cells Sarna, Gregory P. / University of California Los Angeles
NIH 1988 N01 CM	Phase I Clinical Trial of Gm-Csf Sarna, Gregory P. / University of California Los Angeles
NIH 1987 N01 CM	Phase Ib Trial of Immunotherapy/IL-2-Cytotoxic Cells Sarna, Gregory P. / University of California Los Angeles

Publications

Sarna, G; Machleder, H; Collins, J et al. (1994) A comparative study of intravenous versus intralymphatic interleukin-2, with assessment of effects of interleukin-2 on both peripheral blood and thoracic-duct lymph. J Immunother Emphasis Tumor Immunol 15:140-6

Comments

Be the first to comment on Gregory Sarna's grant